Genialis Presents New Clinical Biomarker Findings at SITC, BioTechX
I/ML technology used to enhance drug development included in [...]
Predicting benefit from maintenance durvalumab after first-line chemotherapy (1L CTx) in oesophagogastric adenocarcinoma (OGA) using a novel tumour microenvironment (TME) RNA assay
This study evaluates the efficacy of maintenance durvalumab in [...]
Genialis Updates ResponderID, Enhancing Data Flywheel for Improved Clinical Biomarker Discovery
AI/ML technology helps therapeutic companies improve likelihood of clinical [...]
What’s in a Name?: Endpoint Health’s Patient-Centric Northstar with Jason Springs | Podcast #27
Welcome to Talking Precision Medicine — the podcast in [...]
Genialis’ ResponderID™ Named a Fast Company 2022 World Changing Idea
The winners of Fast Company’s 2022 World Changing Ideas [...]
Genialis Renews ISO 27001 Certification for Fifth Year Running
Renewed credentials underscore the computational precision medicine company’s commitment to [...]
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Navicixizumab plus paclitaxel demonstrated promising clinical activity in bevacizumab-treated and -naive patients with platinum-resistant ovarian cancer, with manageable toxicity.
Genialis Releases Improved Version of Expressions for Faster, More Secure Multi-Omics Processing and Data Management
Cloud software for bioinformatics and systems biology is relaunched [...]
Xerna™ TME Panel: A pan-cancer RNA-based investigational assay designed to predict patient response to angiogenic- and immune-targeted therapies
The Xerna™ TME Panel is a pan-cancer RNA-based investigational [...]
Genialis ResponderID to Use Xerna™ TME Panel to Improve Targeted Therapy Selection
Biomarker discovery platform will incorporate pan-cancer tumor microenvironment classifier [...]
